"Chronic diseases and degenerative conditions are strongly linked with the geriatric syndrome of frailty and account for a disproportionate percentage of the health care budget. Frailty increases the risk of falls, hospitalization, institutionalization, disability, and death. Although exercise and nutritional supplementation provide benefit to frail patients, there are currently no specific therapies for frailty."
A phase I and Phase II clinical trial CRATUS found intravenous allogeneic MSCs safe in individuals with aging frailty and produced significant benefits in measures of physical performance as well as inflammatory biomarkers.
https://www.frontiersin.org/articles/10.3389/fnut.2018.00108/full
